IQVIA (NYSE:IQV – Get Rating) had its target price upped by research analysts at Barclays from $230.00 to $250.00 in a report released on Tuesday, The Fly reports. Barclays’s price objective would indicate a potential upside of 16.96% from the company’s previous close.
IQV has been the subject of a number of other research reports. StockNews.com upgraded IQVIA from a “hold” rating to a “buy” rating in a report on Friday. JPMorgan Chase & Co. boosted their target price on IQVIA from $257.00 to $263.00 and gave the stock an “overweight” rating in a report on Monday, February 27th. Truist Financial decreased their target price on IQVIA from $265.00 to $244.00 in a report on Monday, May 1st. Guggenheim decreased their target price on IQVIA from $266.00 to $258.00 in a report on Friday, April 28th. Finally, Wells Fargo & Company decreased their target price on IQVIA from $235.00 to $220.00 in a report on Monday, May 1st. One investment analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $254.50.
IQVIA Trading Down 0.1 %
Shares of IQV opened at $213.74 on Tuesday. IQVIA has a twelve month low of $165.75 and a twelve month high of $249.11. The firm has a market capitalization of $39.66 billion, a P/E ratio of 38.44, a price-to-earnings-growth ratio of 2.16 and a beta of 1.39. The company has a current ratio of 0.80, a quick ratio of 0.80 and a debt-to-equity ratio of 1.99. The stock’s fifty day simple moving average is $199.87 and its 200 day simple moving average is $206.88.
IQVIA (NYSE:IQV – Get Rating) last released its quarterly earnings data on Thursday, April 27th. The medical research company reported $2.13 EPS for the quarter, missing analysts’ consensus estimates of $2.21 by ($0.08). IQVIA had a return on equity of 30.95% and a net margin of 7.28%. The firm had revenue of $3.65 billion during the quarter, compared to analysts’ expectations of $3.61 billion. On average, equities research analysts forecast that IQVIA will post 9.23 earnings per share for the current year.
Insider Activity
In other news, insider Kevin C. Knightly sold 5,820 shares of the stock in a transaction that occurred on Monday, June 5th. The stock was sold at an average price of $201.89, for a total transaction of $1,174,999.80. Following the completion of the transaction, the insider now directly owns 1,973 shares in the company, valued at approximately $398,328.97. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 1.50% of the company’s stock.
Institutional Investors Weigh In On IQVIA
Institutional investors and hedge funds have recently made changes to their positions in the company. Hanson & Doremus Investment Management raised its position in shares of IQVIA by 300.0% during the 1st quarter. Hanson & Doremus Investment Management now owns 144 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 108 shares in the last quarter. Glassy Mountain Advisors Inc. acquired a new stake in shares of IQVIA during the 4th quarter valued at approximately $31,000. Spire Wealth Management raised its position in shares of IQVIA by 40.3% during the 4th quarter. Spire Wealth Management now owns 167 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 48 shares in the last quarter. AllSquare Wealth Management LLC acquired a new stake in shares of IQVIA during the 1st quarter valued at approximately $36,000. Finally, Hollencrest Capital Management acquired a new stake in shares of IQVIA during the 4th quarter valued at approximately $41,000. 86.93% of the stock is owned by institutional investors and hedge funds.
About IQVIA
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.